Neuroprotection Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Neuroprotection Market size was valued at around USD 38.3 billion in 2023 and is estimated to reach over USD 70.7 billion by 2032. Neuroprotection refers to substances or interventions aimed at safeguarding neuron structure and function in the brain and nervous system. Its goal is to hinder the progression of neurodegenerative diseases, reduce injury damage, and enhance overall nervous system health. The global prevalence of neurological disorders, such as Alzheimer's, Parkinson's, and multiple sclerosis, is on the rise due to factors such as aging populations, lifestyle changes, and improved diagnostic methods.
According to Alzheimer's Disease International (ADI), the global dementia population exceeded 55 million in 2020. Projections suggest it will almost double every 20 years, reaching 78 million by 2030 and 139 million by 2050, with the majority of this rise occurring in developing countries. Currently, 60% of people with dementia are in low and middle-income nations, expected to increase to 71% by 2050. These conditions cause progressive neuron damage and impaired nervous system function, leading to a growing demand for neuroprotection treatments.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Neuroprotection Market size in 2023: | USD 38.3 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2023 - 2032 CAGR: | 7.1 |
| 2023 Value Projection: | USD 70.7 Billion |
| Historical Data for: | 2018 – 2023 |
| No of Pages: | 186 |
| Tables, Charts & Figures: | 290 |
| Segments Covered: | Product, Route of Administration, Application, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
Growing investments in research and development by pharmaceutical companies, academic institutions, and government agencies are driving innovation in neuroprotection therapeutics, particularly for conditions such as Alzheimer's, and Parkinson’s disease therapeutics. This leads to the development of novel drugs, therapies, and technologies targeting neuroprotection, thus expanding the market.
The global population is aging rapidly, with a significant increase in the proportion of elderly individuals in many countries. Aging is a major risk factor for neurodegenerative diseases and age-related cognitive decline, leading to a higher prevalence of conditions such as Alzheimer's and Parkinson's diseases.
For instance, according to the World Health Organization (WHO), by 2030, one-sixth of the global population will be aged 60 or older, increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of individuals aged 60 and above is expected to double to 2.1 billion, with the number of those aged 80 or older tripling to 426 million. Thus, as the elderly population grows, there is a corresponding rise in demand for neuroprotection therapies to address age-related neurological disorders and maintain cognitive function in older adults.
Based on product, the market is segmented into antioxidants, apoptosis inhibitors, anti-inflammatory agents, glutamate antagonists, metal ion chelators, antidepressants, stimulants, neurotrophic factors (NTFs), and other products. The antioxidants segment is estimated to account for USD 14.7 billion by 2032.
Based on route of administration, the neuroprotection market is segmented into oral, intravenous, and other routes of administration. The oral segment held a substantial revenue of USD 24.9 billion in 2023.
Based on application, the neuroprotection market is segmented into neurodegenerative diseases, stroke and ischemic injury, traumatic brain injury (TBI), depression and bipolar disorders, spinal cord injury, and other neurological disorders. The neurodegenerative diseases segment held a substantial revenue of USD 11.8 billion in 2023.
Based on distribution channel, the neuroprotection market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. The hospital pharmacies segment is anticipated to reach USD 30.4 billion by 2032 in the market, primarily due to its pivotal role in providing access to essential medications for patients with neurological disorders.
In 2023, North America held a significant market share of 40.6% in the neuroprotection market and is predicted to witness substantial market growth.
The neuroprotection industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the neuroprotection industry include:
Market, By Product
Market, By Route of Administration
Market, By Application
Market, By Distribution Channel
The above information is provided for the following regions and countries:
North America neuroprotection industry held 40.6% of the market revenue share in 2023 and will see expansion till 2032 owing to the presence of advanced healthcare infrastructure and research facilities.
The antioxidants product segment is estimated to reach USD 14.7 billion by 2032, led by ongoing research underscoring the potential for slowing disease progression and preserving cognitive function.
Neuroprotection market from the oral route of administration segment recorded USD 24.9 billion in valuation in 2023, due to advancements in pharmaceutical formulations to improve efficacy, bioavailability, and stability of oral neuroprotection agents.
Neuroprotection industry size was USD 38.3 billion in 2023 and is estimated to exceed USD 70.7 billion by 2032 driven by rising need for safeguarding neuron structure and function in the brain and nervous system.